Shares of BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report) traded down 3.8% during trading on Wednesday . The company traded as low as $1.46 and last traded at $1.49. 43,621 shares were traded during mid-day trading, an increase of 23% from the average session volume of 35,439 shares. The stock had previously closed at $1.55.
BeyondSpring Stock Down 4.0 %
The stock’s 50 day simple moving average is $1.70 and its 200 day simple moving average is $1.86.
BeyondSpring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.
Read More
- Five stocks we like better than BeyondSpring
- What Investors Need to Know to Beat the Market
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- Pros And Cons Of Monthly Dividend Stocks
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- Airline Stocks – Top Airline Stocks to Buy Now
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
